Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tirzepatide (Primary)
Indications Obesity
Focus Registrational; Therapeutic Use
Acronyms SURMOUNT-CN
Sponsors Eli Lilly and Company

Most Recent Events

06 Oct 2023 Results assessing effect of TZP in Chinese adults with obesity or with over-weight and weight-related comorbidities presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
18 Jan 2023 Status changed from active, no longer recruiting to completed.
26 Dec 2022 Planned End Date changed from 12 Dec 2022 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight